Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL

NCT03249870 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)

Interventions

DRUG: Inotuzumab ozogamicin (INO)

Sponsor

Versailles Hospital